Skip to main content
Top
Published in: Pituitary 6/2014

01-12-2014

Downregulation of Insulin-like growth factor binding protein 6 is associated with ACTH-secreting pituitary adenoma growth

Authors: Yakun Yang, Miaomiao Sheng, Fengming Huang, Dechao Bu, Xiaohai Liu, Yong Yao, Congxin Dai, Bowen Sun, Jindong Zhu, Yonghui Jiao, Zhenqing Wei, Huijuan Zhu, Lin Lu, Yi Zhao, Chengyu Jiang, Renzhi Wang

Published in: Pituitary | Issue 6/2014

Login to get access

Abstract

Background

Adrenocorticotrophic hormone (ACTH)-dependent Cushing’s syndrome, called Cushing disease, is caused by a corticotroph tumor of the pituitary gland. Insulin-like growth factor binding protein 6 (IGFBP6), which regulates insulin-like growth factor (IGF) activity and inhibits several IGF2-dependent cancer growths, plays a pivotal role in the tumorigenesis of malignancy, but its roles in ACTH-secreting pituitary adenomas remain unclear.

Objective

To investigate IGFBP6 expression in ACTH-secreting pituitary adenomas, and its involvement in tumor growth.

Methods

Sporadic ACTH-secreting pituitary adenomas specimens (n = 41) and adjacent non-tumorous pituitary tissues (n = 9) were collected by transphenoidal surgery. IGFBP6 expression was assessed by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and validated by Western blotting. Associations of IGFBP6 expression with maximum tumor diameter or Ki-67 labeling index were evaluated in ACTH-secreting pituitary adenomas.

Results

IGFBP6 mRNA and protein expression were both decreased in ACTH-secreting pituitary adenomas, compared to adjacent non-tumorous pituitary tissues (P < 0.01). IGFBP6 expression was correlated inversely with maximum tumor diameter (Rho = −0.53, P < 0.0001) and Ki-67 levels (Rho = −0.52, P < 0.05). Moreover, IGFBP6 downregulation activated PI3 K-AKT-mTOR pathway in ACTH-secreting pituitary adenomas.

Conclusions

IGFBP6 attenuation in ACTH-secreting pituitary adenomas is associated with tumor growth, through activation of PI3K-AKT-mTOR pathway. The finding underlies IGFBP6 roles in Cushing disease and would potentially provide a novel target of medical therapies.
Literature
2.
go back to reference Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER Jr (2002) The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 96:195–208PubMedCrossRef Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER Jr (2002) The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 96:195–208PubMedCrossRef
3.
go back to reference Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454–2462PubMedCentralPubMedCrossRef Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454–2462PubMedCentralPubMedCrossRef
4.
go back to reference Kaptain GJ, Vincent DA, Sheehan JP, Laws ER Jr (2008) Transsphenoidal approaches for the extracapsular resection of midline suprasellar and anterior cranial base lesions. Neurosurgery 62:1264–1271PubMedCrossRef Kaptain GJ, Vincent DA, Sheehan JP, Laws ER Jr (2008) Transsphenoidal approaches for the extracapsular resection of midline suprasellar and anterior cranial base lesions. Neurosurgery 62:1264–1271PubMedCrossRef
5.
go back to reference Gadelha M, Neto LV. (2014) Efficacy of medical treatment in Cushing's disease: a systematic review. Clin Endocrinol (Oxf) 80:1–12 Gadelha M, Neto LV. (2014) Efficacy of medical treatment in Cushing's disease: a systematic review. Clin Endocrinol (Oxf) 80:1–12
6.
7.
8.
go back to reference Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW (1997) Gene expression profiles in normal and cancer cells. Science 276:1268–1272PubMedCrossRef Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW (1997) Gene expression profiles in normal and cancer cells. Science 276:1268–1272PubMedCrossRef
9.
go back to reference Gallicchio MA, Kneen M, Hall C, Scott AM, Bach LA (2001) Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growth in vivo. Int J Cancer 94:645–651PubMedCrossRef Gallicchio MA, Kneen M, Hall C, Scott AM, Bach LA (2001) Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growth in vivo. Int J Cancer 94:645–651PubMedCrossRef
10.
go back to reference Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824–854PubMedCrossRef Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824–854PubMedCrossRef
11.
go back to reference Gallicchio MA, Kaun C, Wojta J, Binder B, Bach LA (2003) Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro. J Cell Physiol 197:131–138PubMedCrossRef Gallicchio MA, Kaun C, Wojta J, Binder B, Bach LA (2003) Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro. J Cell Physiol 197:131–138PubMedCrossRef
12.
go back to reference Sueoka N, Lee HY, Wiehle S, Cristiano RJ, Fang B, Ji L, Roth JA, Hong WK, Cohen P, Kurie JM (2000) Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. Oncogene 19:4432–4436PubMedCrossRef Sueoka N, Lee HY, Wiehle S, Cristiano RJ, Fang B, Ji L, Roth JA, Hong WK, Cohen P, Kurie JM (2000) Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. Oncogene 19:4432–4436PubMedCrossRef
13.
go back to reference Vogel T (2013) Insulin/IGF-signalling in embryonic and adult neural proliferation and differentiation in the mammalian central nervous system. doi:10.5772/54946 Vogel T (2013) Insulin/IGF-signalling in embryonic and adult neural proliferation and differentiation in the mammalian central nervous system. doi:10.​5772/​54946
14.
go back to reference Werner H, Weinstein D, Bentov I (2008) Similarities and differences between insulin and IGF-I: structures, receptors, and signalling pathways. Arch Physiol Biochem 114:17–22PubMedCrossRef Werner H, Weinstein D, Bentov I (2008) Similarities and differences between insulin and IGF-I: structures, receptors, and signalling pathways. Arch Physiol Biochem 114:17–22PubMedCrossRef
15.
go back to reference Fumagalli L, Campa CC, Germena G, Lowell CA, Hirsch E, Berton G (2013) Class I phosphoinositide-3-kinases and SRC kinases play a nonredundant role in regulation of adhesion-independent and -dependent neutrophil reactive oxygen species generation. J Immunol 190:3648–3660PubMedCrossRef Fumagalli L, Campa CC, Germena G, Lowell CA, Hirsch E, Berton G (2013) Class I phosphoinositide-3-kinases and SRC kinases play a nonredundant role in regulation of adhesion-independent and -dependent neutrophil reactive oxygen species generation. J Immunol 190:3648–3660PubMedCrossRef
17.
go back to reference Yamada S, Fukuhara N, Nishioka H, Takeshita A, Inoshita N, Ito J, Takeuchi Y (2012) Surgical management and outcomes in patients with Cushing disease with negative pituitary magnetic resonance imaging. World Neurosurg 77:525–532PubMedCrossRef Yamada S, Fukuhara N, Nishioka H, Takeshita A, Inoshita N, Ito J, Takeuchi Y (2012) Surgical management and outcomes in patients with Cushing disease with negative pituitary magnetic resonance imaging. World Neurosurg 77:525–532PubMedCrossRef
18.
go back to reference Mampalam TJ, Wilson CB (1988) Transsphenoidal microsurgery for cushing disease a report of 216 cases. Ann Intern Med 109(6):487–493PubMedCrossRef Mampalam TJ, Wilson CB (1988) Transsphenoidal microsurgery for cushing disease a report of 216 cases. Ann Intern Med 109(6):487–493PubMedCrossRef
19.
go back to reference Kiehna EN, Keil M, Lodish M, Stratakis C, Oldfield EH (2010) Pseudotumor cerebri after surgical remission of Cushing’s disease. J Clin Endocrinol Metab 95:1528–1532PubMedCentralPubMedCrossRef Kiehna EN, Keil M, Lodish M, Stratakis C, Oldfield EH (2010) Pseudotumor cerebri after surgical remission of Cushing’s disease. J Clin Endocrinol Metab 95:1528–1532PubMedCentralPubMedCrossRef
20.
go back to reference Monteith SJ, Starke RM, Jane JA Jr, Oldfield EH (2012) Use of the histological pseudocapsule in surgery for Cushing disease: rapid postoperative cortisol decline predicting complete tumor resection. J Neurosurg 116:721–727PubMedCrossRef Monteith SJ, Starke RM, Jane JA Jr, Oldfield EH (2012) Use of the histological pseudocapsule in surgery for Cushing disease: rapid postoperative cortisol decline predicting complete tumor resection. J Neurosurg 116:721–727PubMedCrossRef
22.
go back to reference Jagannathan J, Smith R, DeVroom HL, Vortmeyer AO, Stratakis CA, Nieman LK, Oldfield EH (2009) Outcome of using the histological pseudocapsule as a surgical capsule in Cushing disease. J Neurosurg 111:531–539PubMedCentralPubMedCrossRef Jagannathan J, Smith R, DeVroom HL, Vortmeyer AO, Stratakis CA, Nieman LK, Oldfield EH (2009) Outcome of using the histological pseudocapsule as a surgical capsule in Cushing disease. J Neurosurg 111:531–539PubMedCentralPubMedCrossRef
23.
go back to reference Vance ML (2003) Perioperative management of patients undergoing pituitary surgery. Endocrinol Metab Clin North Am 32:355–365PubMedCrossRef Vance ML (2003) Perioperative management of patients undergoing pituitary surgery. Endocrinol Metab Clin North Am 32:355–365PubMedCrossRef
24.
go back to reference Kato M, Ishizaki A, Hellman U, Wernstedt C, Kyogoku M, Miyazono K, Heldin CH, Funa K (1995) A human keratinocyte cell line produces two autocrine growth inhibitors, transforming growth factor-beta and insulin-like growth factor binding protein-6, in a calcium- and cell density-dependent manner. J Biol Chem 270:12373–12379PubMedCrossRef Kato M, Ishizaki A, Hellman U, Wernstedt C, Kyogoku M, Miyazono K, Heldin CH, Funa K (1995) A human keratinocyte cell line produces two autocrine growth inhibitors, transforming growth factor-beta and insulin-like growth factor binding protein-6, in a calcium- and cell density-dependent manner. J Biol Chem 270:12373–12379PubMedCrossRef
26.
go back to reference Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM (2008) The diagnosis of cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:1526–1540PubMedCentralPubMedCrossRef Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM (2008) The diagnosis of cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:1526–1540PubMedCentralPubMedCrossRef
27.
go back to reference Aghi MK (2008) Management of recurrent and refractory Cushing disease. Nat Clin Pract Endocrinol Metab 4:560–568PubMedCrossRef Aghi MK (2008) Management of recurrent and refractory Cushing disease. Nat Clin Pract Endocrinol Metab 4:560–568PubMedCrossRef
28.
go back to reference Hwa V, Oh Y, Rosenfeld RG (1999) The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20:761–787PubMed Hwa V, Oh Y, Rosenfeld RG (1999) The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20:761–787PubMed
29.
go back to reference Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3–34PubMed Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3–34PubMed
30.
go back to reference Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, Ng L, Simpson DM, Rosenfeld RG (1996) Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 28:619–637PubMedCrossRef Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, Ng L, Simpson DM, Rosenfeld RG (1996) Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 28:619–637PubMedCrossRef
31.
go back to reference Rajaram S, Baylink DJ, Mohan S (1997) Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18:801–831PubMed Rajaram S, Baylink DJ, Mohan S (1997) Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18:801–831PubMed
32.
go back to reference Djiogue S, Nwabo Kamdje AH, Vecchio L, Kipanyula MJ, Farahna M, Aldebasi Y, Seke Etet PF (2013) Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer 20:R1–R17PubMedCrossRef Djiogue S, Nwabo Kamdje AH, Vecchio L, Kipanyula MJ, Farahna M, Aldebasi Y, Seke Etet PF (2013) Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer 20:R1–R17PubMedCrossRef
33.
go back to reference Koyama N, Zhang J, Huqun, Miyazawa H, Tanaka T, Su X, Hagiwara K (2008) Identification of IGFBP-6 as an effector of the tumor suppressor activity of SEMA3B. Oncogene 27:6581–6589PubMedCrossRef Koyama N, Zhang J, Huqun, Miyazawa H, Tanaka T, Su X, Hagiwara K (2008) Identification of IGFBP-6 as an effector of the tumor suppressor activity of SEMA3B. Oncogene 27:6581–6589PubMedCrossRef
34.
go back to reference Kuo YS, Tang YB, Lu TY, Wu HC, Lin CT (2010) IGFBP-6 plays a role as an oncosuppressor gene in NPC pathogenesis through regulating EGR-1 expression. J Pathol 222:299–309PubMedCrossRef Kuo YS, Tang YB, Lu TY, Wu HC, Lin CT (2010) IGFBP-6 plays a role as an oncosuppressor gene in NPC pathogenesis through regulating EGR-1 expression. J Pathol 222:299–309PubMedCrossRef
35.
go back to reference Martins AS, Olmos D, Missiaglia E, Shipley J (2011) Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives. Sarcoma 2011:209736PubMedCentralPubMedCrossRef Martins AS, Olmos D, Missiaglia E, Shipley J (2011) Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives. Sarcoma 2011:209736PubMedCentralPubMedCrossRef
Metadata
Title
Downregulation of Insulin-like growth factor binding protein 6 is associated with ACTH-secreting pituitary adenoma growth
Authors
Yakun Yang
Miaomiao Sheng
Fengming Huang
Dechao Bu
Xiaohai Liu
Yong Yao
Congxin Dai
Bowen Sun
Jindong Zhu
Yonghui Jiao
Zhenqing Wei
Huijuan Zhu
Lin Lu
Yi Zhao
Chengyu Jiang
Renzhi Wang
Publication date
01-12-2014
Publisher
Springer US
Published in
Pituitary / Issue 6/2014
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-013-0535-8

Other articles of this Issue 6/2014

Pituitary 6/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine